The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer

(1) Background: Notwithstanding numerous therapeutic advances, 176,000 deaths from breast and lung cancers will occur in the United States in 2021 alone. The tumor microenvironment and its modulation by drugs have gained increasing attention and relevance, especially with the introduction of immunot...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers 2021-10, Vol.13 (19), p.5004
Hauptverfasser:	Leal, Ana S., Moerland, Jessica A., Zhang, Di, Carapellucci, Sarah, Lockwood, Beth, Krieger-Burke, Teresa, Aleiwi, Bilal, Ellsworth, Edmund, Liby, Karen T.
Format:	Artikel
Sprache:	eng
Schlagworte:	Agonists Animal models Antibodies Breast cancer CD25 antigen CD4 antigen CD8 antigen Clinical trials Cytotoxicity ErbB-2 protein FDA approval Flow cytometry Immunocompetence Immunodeficiency Immunomodulation Immunosuppressive agents Immunotherapy K-Ras protein Laboratory animals Lung cancer Lymphocytes T PD-1 protein Retinoid X receptors T-cell lymphoma Transcription factors Tumor microenvironment Tumorigenesis Tumors Vinyl carbamate Xenografts
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!